VistaGen raises $36M for stem cell tech

South San Francisco-based VistaGen Therapeutics says it's raised $36 million, selling shares to Bergamo Acquisition for 50 cents apiece. The biotech says it will use the cash to "accelerate and expand its stem cell technology-based drug rescue programs." "Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated CEO Shawn K. Singh. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.